A Case of Metastatic Rectal Cancer that Maintained Long Survival by Capecitabine and Bevacizumab after Salvage-line Chemotherapy

A woman in her 50s underwent low anterior resection, segmental small intestinal resection, and partial cystectomy for advanced rectal cancer. She received adjuvant therapy with UFT/LV. Seven years after the primary resection, local recurrence was diagnosed. We were able to perform surgery and R0 resection. Four years after the second operation, local recurrence was identified, but it was unresectable. She was treated with FOLFOX, FOLFIRI, and FTD/TPI. Since these che-motherapies resulted in progressive disease, capecitabine plus bevacizumab were administered as a late-line chemotherapy. Two years after treatment with the chemotherapy, tumor growth had been controlled. She is still alive 19 years after the first operation and is able to continue treatment with capecitabine plus bevacizumab.